Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Christmas is just around the corner, and with that comes the much anticipated 77th Annual Yuletide Madrigal Feaste. The ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

Chief Executive Officer of Madrigal, Bill Sibold, highlighted the successful launch of Rezdiffra™ (resmetirom) in the U.S., emphasizing strong adoption by prescribers and increasing patient ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Analyst Ritu Baral from TD Cowen maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) and keeping the price ...